腺嘌呤核苷及其受体作为治疗靶点：概述。
Adenosine and its receptors as therapeutic targets: An overview.
机构信息
ASBASJSM College of Pharmacy, Bela, Ropar, India.
出版信息
Saudi Pharm J. 2013 Jul;21(3):245-53. doi: 10.1016/j.jsps.2012.05.011. Epub 2012 Jun 23.
Abstract
The main goal of the authors is to present an overview of adenosine and its receptors, which are G-protein coupled receptors. The four known adenosine receptor subtypes are discussed along with the therapeutic potential indicating that these receptors can serve as targets for various dreadful diseases.
摘要
作者的主要目标是介绍腺苷及其受体的概述，这些受体是 G 蛋白偶联受体。讨论了四种已知的腺苷受体亚型，并探讨了其治疗潜力，表明这些受体可以作为各种可怕疾病的靶点。
相似文献
1
Adenosine and its receptors as therapeutic targets: An overview.腺嘌呤核苷及其受体作为治疗靶点：概述。
Saudi Pharm J. 2013 Jul;21(3):245-53. doi: 10.1016/j.jsps.2012.05.011. Epub 2012 Jun 23.
2
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.在人A2B和A3受体亚型上具有高效能的三唑并喹唑啉腺苷拮抗剂（CGS 15943）的衍生物。
J Med Chem. 1998 Jul 16;41(15):2835-45. doi: 10.1021/jm980094b.
3
Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.脑腺苷受体作为神经退行性疾病治疗干预的靶点。
Ann N Y Acad Sci. 1999;890:79-92. doi: 10.1111/j.1749-6632.1999.tb07983.x.
4
Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells.刺激腺苷 A3 受体而非 A1 或 A2 受体可促进视网膜神经节细胞的轴突生长。
Exp Eye Res. 2018 May;170:160-168. doi: 10.1016/j.exer.2018.02.019. Epub 2018 Feb 24.
5
Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy.血小板腺苷受体作为抗血小板治疗的潜在靶点。
Int J Mol Sci. 2019 Nov 3;20(21):5475. doi: 10.3390/ijms20215475.
6
New substituted 9-alkylpurines as adenosine receptor ligands.新型取代的9-烷基嘌呤作为腺苷受体配体。
Bioorg Med Chem. 1998 May;6(5):523-33. doi: 10.1016/s0968-0896(98)00007-8.
7
Adenosine receptors and Huntington's disease.腺苷受体与亨廷顿舞蹈症
Int Rev Neurobiol. 2014;119:195-232. doi: 10.1016/B978-0-12-801022-8.00010-6.
8
Perspective and Potential of A2A and A3 Adenosine Receptors as Therapeutic Targets for the Treatment of Rheumatoid Arthritis.A2A 和 A3 腺苷受体作为类风湿关节炎治疗靶点的展望与潜力。
Curr Pharm Des. 2019;25(26):2859-2874. doi: 10.2174/1381612825666190710111658.
9
A Adenosine Receptor Antagonists and their Potential in Neurological Disorders.腺苷受体拮抗剂及其在神经紊乱中的潜在应用。
Curr Med Chem. 2022 Aug 6;29(28):4780-4795. doi: 10.2174/0929867329666220218094501.
10
Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs.对A2a受体缺陷小鼠的分析显示，淋巴器官中A2b、A1和A3腺苷受体的表达没有显著的代偿性增加。
Biochem Pharmacol. 2003 Jun 15;65(12):2081-90. doi: 10.1016/s0006-2952(03)00158-8.
引用本文的文献
1
Therapeutic potential of adenosine receptor modulators in cancer treatment.腺苷受体调节剂在癌症治疗中的治疗潜力。
RSC Adv. 2025 Jun 17;15(26):20418-20445. doi: 10.1039/d5ra02235e. eCollection 2025 Jun 16.
2
Overexpression of adenosine receptor (A1, A2a, A2b, A3) genes in esophageal tumor tissue: A2b adenosine receptor as a potential biomarker and anticancer target.食管肿瘤组织中腺苷受体（A1、A2a、A2b、A3）基因的过表达：A2b腺苷受体作为一种潜在的生物标志物和抗癌靶点。
J Appl Genet. 2025 Jun 12. doi: 10.1007/s13353-025-00981-5.
3
Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.司美格鲁肽和腺苷可减轻肥胖诱导的肾损伤，并观察到对Txnip/NLRP3通路的调节作用。
Diabetol Metab Syndr. 2025 May 24;17(1):164. doi: 10.1186/s13098-025-01736-2.
4
β-Lapachone Exerts Hypnotic Effects via Adenosine A Receptor in Mice.β-拉帕醌通过腺苷A受体对小鼠发挥催眠作用。
Biomol Ther (Seoul). 2024 Sep 1;32(5):531-539. doi: 10.4062/biomolther.2024.106. Epub 2024 Aug 21.
5
Current Understanding of the Role of Adenosine Receptors in Cancer.目前对腺苷受体在癌症中的作用的认识。
Molecules. 2024 Jul 26;29(15):3501. doi: 10.3390/molecules29153501.
6
Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review.纳米材料作为克服血脑屏障的药物递送剂：综述
ADMET DMPK. 2023 Oct 31;12(1):63-105. doi: 10.5599/admet.2043. eCollection 2024.
7
Energy Regulation in Inflammatory Sarcopenia by the Purinergic System.嘌呤能系统在炎症性肌肉减少症中的能量调节。
Int J Mol Sci. 2023 Nov 29;24(23):16904. doi: 10.3390/ijms242316904.
8
Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy.药物递送至大脑的策略：关于腺苷受体调节用于中枢神经系统疾病治疗的综述
Pharmaceutics. 2023 Oct 10;15(10):2441. doi: 10.3390/pharmaceutics15102441.
9
On the participation of adenosinergic receptors in the reconsolidation of spatial long-term memory in male rats.在雄性大鼠中海马腺苷能受体参与空间长时记忆的再巩固过程。
Learn Mem. 2023 Oct 6;30(10):260-270. doi: 10.1101/lm.053785.123. Print 2023 Oct.
10
Dipyridamole activates adenosine A2B receptor and AMPK/cAMP signaling and promotes myogenic differentiation of myoblastic C2C12 cells.双嘧达莫激活腺苷A2B受体和AMPK/cAMP信号通路，并促进成肌细胞C2C12细胞的肌源性分化。
Front Pharmacol. 2023 Sep 12;14:1247664. doi: 10.3389/fphar.2023.1247664. eCollection 2023.
本文引用的文献
1
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.A2 和 A3 腺苷受体的治疗潜力：新型专利配体综述。
Expert Opin Ther Pat. 2012 Apr;22(4):369-90. doi: 10.1517/13543776.2012.669375. Epub 2012 Mar 22.
2
Purinergic modulation of the excitatory synaptic input onto rat striatal neurons.嘌呤能调制大鼠纹状体神经元的兴奋性突触传入。
Neuropharmacology. 2012 Mar;62(4):1756-66. doi: 10.1016/j.neuropharm.2011.12.001. Epub 2011 Dec 13.
3
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.新型的腺苷 A2A 拮抗剂 Lu AA47070 可逆转多巴胺 D2 受体阻断引起的运动和动机效应。
Pharmacol Biochem Behav. 2012 Jan;100(3):498-505. doi: 10.1016/j.pbb.2011.10.015. Epub 2011 Oct 20.
4
Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.在 DOCA-盐高血压大鼠中，血管收缩反应对内皮衍生的收缩因子尿苷腺苷四磷酸的改变具有区域特异性。
Pharmacol Res. 2012 Jan;65(1):81-90. doi: 10.1016/j.phrs.2011.09.005. Epub 2011 Sep 14.
5
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.A(2A) 腺苷受体拮抗剂在帕金森病治疗中的过去、现在和未来。
Pharmacol Ther. 2011 Dec;132(3):280-99. doi: 10.1016/j.pharmthera.2011.07.004. Epub 2011 Jul 23.
6
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.精神分裂症的腺苷假说——药物治疗的机会。
Neuropharmacology. 2012 Mar;62(3):1527-43. doi: 10.1016/j.neuropharm.2011.01.048. Epub 2011 Feb 17.
7
Structure-based discovery of A2A adenosine receptor ligands.基于结构的 A2A 腺苷受体配体的发现。
J Med Chem. 2010 May 13;53(9):3748-55. doi: 10.1021/jm100240h.
8
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.2-氨基-5-苯甲酰基-4-苯基噻唑：高效且选择性的腺苷 A1 受体拮抗剂的研发。
Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. doi: 10.1016/j.bmc.2010.01.072. Epub 2010 Feb 4.
9
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.1-烷基-8-（哌嗪-1-磺酰基）苯基黄嘌呤：腺苷A2B受体拮抗剂及一种具有亚纳摩尔亲和力和亚型特异性的新型放射性配体的研发与特性研究
J Med Chem. 2009 Jul 9;52(13):3994-4006. doi: 10.1021/jm900413e.
10
The adenosinergic immunomodulatory drugs.腺嘌呤核苷免疫调节药物。
Curr Opin Pharmacol. 2009 Aug;9(4):501-6. doi: 10.1016/j.coph.2009.05.005. Epub 2009 Jun 17.
Zotero 插件